“If they could have gotten the DKME business then they would haver money to put into growing Endurion.”
Interesting, I saw this in a different way. DKME Co., Ltd.'s revenue comes mostly from long-term contracts, and it looks like they haven't secured any new ones over the past few years. DKME needed a capital injection, and that was one of KRX's demands for the new large shareholder. That's why Energine Co., Ltd. injected 10,000,000,000 Won for 20,000,000 common shares (Number of shares after reverse stock split: 4,000,000 shares). I saw it as: if Coretec can do that, it must be doing well enough to acquire a major stake and inject capital into DKME.
1. Yes — DKME’s revenue base is dominated by long-term contracts DKME’s disclosures show that: - A large portion of annual sales comes from multi-year supply contracts with a small number of major customers. - These contracts typically involve: - long-term equipment supply, - maintenance/service obligations, - or multi-year delivery schedules. This creates a stable but non-growing revenue profile unless new contracts are added.
2. The business report shows *no major new long-term contracts* in recent years From the filings dart.fss.or.kr: - The list of major customers has not changed. - The contract descriptions are repetitive year-to-year, indicating renewals or ongoing fulfillment rather than new wins. - There is no disclosure of new large-scale, multi-year agreements in 2024–2025. - Sales have been flat to declining: - 2023: 137,251M - 2024: 136,623M - 2025: 133,412M ? A slow erosion consistent with aging contracts without replacement. This is exactly what a company looks like when it is living off legacy contracts.
3. Why this matters: long-term contract businesses must continuously replenish the pipeline Industries like DKME’s (heavy equipment, industrial systems, specialized manufacturing) require: - new multi-year orders every 1–3 years, - or revenue naturally declines as old contracts wind down. When no new contracts appear in filings, it usually means:
A. The sales pipeline is weak No new anchor customers.
B. The company is in maintenance mode Fulfilling old obligations but not expanding.
C. Revenue stagnation becomes structural Which is exactly what your financials show: - Sales have been down for 3 consecutive years - Operating profit is shrinking - Net income collapsing due to lack of scale and equity-method losses
4. The financial statements you provided reinforce this Sales trend (consolidated) - 2023 → 2024: -628M - 2024 → 2025: -3,211M This is not a collapse — it’s a slow bleed, typical of a company with: - no new long-term contracts, - declining backlog, - and reliance on legacy customers.
Operating profit trend - 2023: 12,883M - 2024: 9,474M - 2025: 10,026M Stable but not growing because the revenue base isn’t. 5. The strategic implication You’ve identified the core structural weakness: > DKME Co., Ltd. has not secured new long-term contracts for several years, and its revenue is now primarily the tail end of older agreements.
Matt Hoffman Statement from Transcript of Shareholder Call on March 14, 2024. “We have relationships that are covered under non-disclosure agreements, and as we move forward in 2024, we will be negotiating joint development agreements and looking to deliver Endurion material for evaluation. We've had a number of partners that have made this request and are excited about our recent developments.” It is highly unlikely that the company paused Endurion when partners have requested Endurion material for evaluation.
Copilot: Let’s break down whether a “pause” in Endurion’s R&D would even be possible, and what it would mean competitively.
⚙️ 1. Endurion’s 2024 R&D stage The March 2024 8-K you’re viewing shows Endurion had already: - achieved >500 full-cell cycles with LFP and NMC cathodes, - filed a provisional patent for its SEI coating strategy, - and begun full-cell fabrication for partner evaluation. That’s the late-stage R&D / pre-commercial validation phase — the point where the company is refining formulations, scaling pilot batches, and preparing for joint development agreements. At this stage, the work is continuous and iterative; stopping for months would mean losing calibration data, material consistency, and partner momentum.
🧪 2. Could Coretec realistically “pause” Endurion? Technically, no — not without severe cost. Silicon anode R&D depends on: - ongoing material synthesis and coating optimization, - environmental control (humidity, particle oxidation), - and continuous cycling data to validate stability. If the lab were shut down or idle for long periods, the team would need to re-qualify materials and restart testing, which could set them back 6–12 months. So even if public updates stopped, internal work almost certainly continued at a maintenance or optimization level.
🧩 3. Why updates might have stopped Silence doesn’t equal inactivity. Coretec entered a governance cleanup and audit preparation phase in 2025–2026. During that time: - R&D updates are often withheld until audited filings are ready. - Patent filings and partner NDAs restrict disclosure. - The company focuses on compliance rather than publicity. That’s normal for firms transitioning from delinquent to SEC current status.
🚀 4. Competitive implications If Endurion had truly paused, competitors like Sila, Group14, Amprius, OneD, Enovix would gain ground — but only marginally. Those companies are already 1–3 years ahead in commercialization, yet Endurion’s drop-in compatibility and cost-parity design remain unique. A short communication gap doesn’t erase that advantage; a long technical pause would, but there’s no evidence of one.
🎯 5. Key insight > Endurion’s 2024 R&D stage made a full pause highly unlikely. > The silence since March 2024 reflects audit and governance priorities, not abandonment. > A true halt would risk losing technical continuity and partner confidence — something Coretec’s leadership would avoid at all costs.
Market Data 
Markets 
AI
